Skip to content
stoqly

Kewaunee Scientific Corp /De/

KEQU Nasdaq Laboratory Apparatus & Furniture Financials FY2017–FY2026

Revenue Total sales reported in the income statement.
$282M
17.3% vs prior year
Operating margin Operating income as a share of revenue.
5.9%
1.5 pts
Net income Profit after all expenses, interest and tax.
$9.6M
15.7%
Free cash flow Cash from operations minus capital spending.
$14.7M
16.5%
Return on capital After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
15.0%
0.8 pts
Market cap Last close times the latest diluted share count, so it is approximate.
—
P/E Last close divided by diluted earnings per share over the last four quarters.
—
On $2.76 EPS (TTM)

What Kewaunee Scientific Corp /De/ does

No business description yet.

Legal name
KEWAUNEE SCIENTIFIC CORP /DE/
Fiscal year ends
April 30, 2026
Latest annual report
10-K · Jun 26, 2026
Accession · CIK
0000055529-26-000020
0000055529

Revenue and margins

Kewaunee Scientific Corp /De/ had $282M of revenue in fiscal 2026, up 17.3% on the year before.

Revenue
Revenue
Margins, % of revenue
Gross Operating Net FCF
Margins, % of revenue
Gross Operating Net FCF

Net income and earnings per share

From fiscal 2017 to 2026, diluted EPS grew 7.6% a year. Loss periods are shown in red.

Net income
Net income
Diluted EPS
Diluted EPS

Returns on capital

After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.

Return on capital, equity and assets (annual)
Return on capital Return on equity Return on assets

Cash flow

Free cash flow was $14.7M in fiscal 2026, 5.2% of revenue. Cash from operations minus capital spending.

Free cash flow
Free cash flow
Cash from operations vs capital spending
Cash from operations Capital spending
Cash from operations vs capital spending
Cash from operations Capital spending

Dividends, buybacks and share count

Kewaunee Scientific Corp /De/ returned $0.0M to shareholders in fiscal 2026, 0% of free cash flow. The diluted share count rose 0.1%.

Dividends and buybacks
Dividends Buybacks
Dividends and buybacks
Dividends Buybacks
Diluted shares outstanding (annual)

Balance sheet

Cash, debt and the ratios that show how comfortably Kewaunee Scientific Corp /De/ can carry it.

Cash vs debt (incl. leases)
Cash Debt
Fiscal year endFY22FY23FY24FY25FY26
Cash and short-term investments $4.4M$8.1M$23.3M$14.9M$10.0M
Debt incl. finance leases $1.9M$3.8M$3.4M$38.9M$20.5M
Net debt / EBITDA −15.5x−0.5x−0.9x1.1x0.5x
Debt / equity 0.0x0.1x0.1x0.6x0.3x
Interest coverage −4.1x3.1x10.2x5.5x4.3x
Current ratio 2.2x2.2x2.4x2.2x2.2x
Quick ratio 1.6x1.6x1.9x1.6x1.5x
Total assets $119M$119M$135M$195M$178M
Total liabilities $82.6M$80.4M$78.6M$128M$101M
Shareholders' equity $35.7M$37.4M$54.8M$64.5M$74.7M
Net debt (− = net cash) −$2.5M−$4.3M−$19.8M$24.0M$10.6M

Insider trades

Open-market purchases and sales by officers, directors and 10% owners, from Form 4 filings. 'Plan' marks trades under a pre-arranged Rule 10b5-1 plan.

Bought, 12 months

$0.0M

0 insiders

Sold, 12 months

$0.0M

0 insiders

Of sales under plans

—

$0.0M

No open-market insider trades in the last 12 months.

Piotroski F-score

Nine pass/fail tests of profitability, funding and efficiency. 8–9 is strong, 0–2 weak.

TestFY17FY18FY19FY20FY21FY22FY23FY24FY25FY26
Net income is positive ✓ ✓ ✓ ✕ ✕ ✕ ✓ ✓ ✓ ✓
Cash from operations is positive ✓ ✓ ✓ ✓ ✓ ✕ ✕ ✓ ✓ ✓
Return on assets rose — ✓ ✕ ✕ ✓ ✕ ✓ ✓ ✕ ✕
Cash from operations exceeds net income ✓ ✕ ✓ ✓ ✓ ✕ ✕ ✓ ✓ ✓
Debt fell relative to assets — ✓ ✓ ✕ ✕ ✓ ✕ ✓ ✕ ✓
Current ratio rose — ✓ ✕ ✓ ✕ ✓ ✓ ✓ ✕ ✕
Share count didn't rise — ✕ ✕ ✓ ✕ ✕ ✕ ✕ ✕ ✕
Gross margin rose — ✓ ✕ ✕ ✓ ✕ ✓ ✓ ✓ ✕
Revenue rose relative to assets — ✓ ✕ ✓ ✕ ✕ ✓ ✕ ✕ ✓
F-score — / 37 / 94 / 95 / 94 / 92 / 95 / 97 / 94 / 95 / 9
Accruals ratio −8.8%2.5%−1.1%−10.3%−5.3%1.7%3.8%−0.6%−2.1%−4.8%
Altman Z'' 6.026.665.504.303.983.804.225.524.314.75

10 years of figures

US$ millions unless stated. Hover a ratio's name for its definition.

Download CSV
Fiscal yearFY17FY18FY19FY20FY21FY22FY23FY24FY25FY26
Income statement
Revenue $139M $158M $147M $148M $147M $169M $219M $204M $240M $282M
Gross profit $26.6M $32.2M $25.3M $23.4M $24.0M $24.2M $35.6M $52.1M $68.9M $80.4M
Research and development $1.2M $1.5M $1.6M $1.8M $1.4M $1.0M $1.0M $0.9M $0.9M $0.9M
Operating income $6.5M $9.9M $2.1M −$2.3M −$1.3M −$2.6M $5.4M $18.3M $17.8M $16.7M
Interest expense $0.3M $0.3M $0.4M $0.5M $0.4M $0.6M $1.7M $1.8M $3.2M $3.9M
Pretax income $6.7M $9.6M $2.1M −$2.9M −$2.6M −$2.5M $4.5M $13.1M $14.8M $13.7M
Income tax $2.1M $4.2M $0.4M $1.8M $1.0M $3.5M $3.1M −$5.9M $3.2M $3.3M
Net income $4.5M $5.3M $1.5M −$4.7M −$3.7M −$6.1M $0.7M $18.8M $11.4M $9.6M
Diluted EPS $1.66 $1.90 $0.55 −$1.70 −$1.33 −$2.20 $0.25 $6.38 $3.83 $3.22
Diluted shares 0.00B 0.00B 0.00B 0.00B 0.00B 0.00B 0.00B 0.00B 0.00B 0.00B
Cash flow
Cash from operations $11.7M $3.2M $2.5M $4.2M $0.9M −$7.9M −$3.8M $19.6M $14.8M $18.6M
Capital expenditure $2.6M $3.4M $4.2M $2.5M $2.4M $1.9M $4.1M $4.4M $2.2M $3.9M
Free cash flow $9.1M −$0.2M −$1.7M $1.7M −$1.5M −$9.8M −$7.9M $15.2M $12.6M $14.7M
Depreciation and amortization $2.7M $2.8M $2.6M $2.7M $2.7M $2.8M $2.9M $3.1M $4.8M $6.3M
Stock-based compensation $0.2M $0.4M $0.2M $0.3M $0.6M $0.7M $0.9M $1.0M $1.4M $2.1M
Acquisitions — — — — — — — $0.0M $28.7M $0.0M
Share buybacks — — — — — — $0.0M $2.0M $1.6M $0.0M
Dividends paid $1.6M $1.8M $2.0M $1.0M $0.0M — — — — —
Dividends and buybacks $1.6M $1.8M $2.0M $1.0M $0.0M — $0.0M $2.0M $1.6M $0.0M
Balance sheet
Cash and short-term investments $12.5M $9.7M $10.6M $4.4M $5.2M $4.4M $8.1M $23.3M $14.9M $10.0M
Total debt $2.4M $1.3M $0.1M $4.7M $6.8M $1.6M $3.6M $3.1M $38.7M $20.2M
Finance lease liabilities — — — $0.1M $0.1M $0.4M $0.2M $0.3M $0.2M $0.4M
Current assets $59.8M $64.4M $65.4M $54.2M $60.5M $91.6M $87.9M $96.8M $118M $105M
Current liabilities $26.9M $27.6M $32.7M $27.1M $34.2M $42.3M $40.1M $40.8M $53.7M $48.4M
Inventory $14.9M $18.5M $17.2M $15.3M $16.5M $23.8M $21.9M $20.7M $32.8M $30.5M
Property and equipment, net $14.0M $14.7M $16.5M $16.3M $16.0M $15.1M $16.4M $17.6M $23.2M $22.4M
Goodwill — — — — — — — $0.0M $12.5M $12.5M
Intangible assets — — — — — — — $0.0M $17.8M $16.3M
Total assets $80.9M $85.1M $87.2M $83.9M $89.4M $119M $119M $135M $195M $178M
Total liabilities $37.7M $36.9M $39.5M $45.2M $47.9M $82.6M $80.4M $78.6M $128M $101M
Shareholders' equity $43.5M $47.7M $47.1M $38.4M $41.2M $35.7M $37.4M $54.8M $64.5M $74.7M
Margins
Gross margin 19.2% 20.3% 17.3% 15.9% 16.3% 14.3% 16.2% 25.5% 28.6% 28.5%
Operating margin 4.7% 6.3% 1.4% −1.6% −0.9% −1.5% 2.4% 9.0% 7.4% 5.9%
EBITDA margin 6.7% 8.0% 3.2% 0.2% 0.9% 0.1% 3.8% 10.5% 9.4% 8.2%
Net margin 3.3% 3.3% 1.0% −3.2% −2.5% −3.6% 0.3% 9.2% 4.7% 3.4%
FCF margin 6.5% −0.1% −1.2% 1.1% −1.0% −5.8% −3.6% 7.5% 5.2% 5.2%
Returns
Return on capital 13.4% 16.4% 4.6% −4.8% −2.4% −6.3% 10.6% 52.8% 15.8% 15.0%
Return on capital employed 12.1% 17.3% 3.9% −4.1% −2.4% −3.4% 6.8% 19.5% 12.6% 12.9%
Return on equity 10.4% 11.6% 3.2% −11.0% −9.2% −15.9% 2.0% 40.7% 19.1% 13.8%
Return on assets 5.6% 6.4% 1.8% −5.5% −4.2% −5.9% 0.6% 14.8% 6.9% 5.2%
Return on tangible equity 10.4% 11.1% 3.2% −12.2% −8.9% −17.2% 2.0% 34.2% 33.4% 20.9%
Growth
Revenue growth — 14.1% −7.3% 0.7% −0.0% 14.5% 30.0% −7.2% 18.0% 17.3%
Net income growth — 17.0% −71.0% −406.5% — — — 2,441.1% −39.2% −15.7%
EPS growth — 14.5% −71.1% −409.1% — — — 2,452.0% −40.0% −15.9%
FCF growth — −102.3% — — −187.6% — — — −16.9% 16.5%
Share count change — 1.9% 0.6% −1.6% 0.4% 0.9% 4.2% 1.2% 1.4% 0.1%
Financial health
Net debt / EBITDA −1.1x −0.7x −2.3x 1.6x 1.3x −15.5x −0.5x −0.9x 1.1x 0.5x
Debt / equity 0.1x 0.0x 0.0x 0.1x 0.2x 0.0x 0.1x 0.1x 0.6x 0.3x
Interest coverage 22.4x 33.2x 5.8x −4.8x −3.4x −4.1x 3.1x 10.2x 5.5x 4.3x
Current ratio 2.2x 2.3x 2.0x 2.0x 1.8x 2.2x 2.2x 2.4x 2.2x 2.2x
Quick ratio 1.7x 1.7x 1.5x 1.4x 1.3x 1.6x 1.6x 1.9x 1.6x 1.5x
Capital allocation
Capex / revenue 1.9% 2.1% 2.9% 1.7% 1.6% 1.1% 1.9% 2.1% 0.9% 1.4%
Stock comp / revenue 0.1% 0.2% 0.1% 0.2% 0.4% 0.4% 0.4% 0.5% 0.6% 0.8%
Payouts / FCF 17.3% — — 61.6% — — — 13.2% 12.6% 0.0%
Quality scores
Piotroski F-score — 7.0 4.0 5.0 4.0 2.0 5.0 7.0 4.0 5.0
Altman Z'' 6.0 6.7 5.5 4.3 4.0 3.8 4.2 5.5 4.3 4.8
Accruals ratio −8.8% 2.5% −1.1% −10.3% −5.3% 1.7% 3.8% −0.6% −2.1% −4.8%

Source: SEC EDGAR XBRL filings (CIK 0000055529). Data updated October 24, 2026. Quarterly fourth quarters are the full year minus the first nine months. For information only — not investment advice. Check the original filings before relying on any figure.

↑ ↓ to move · ↵ to open